SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $1,951,406,063 |
| Positions | 50 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $214,265,600 | 640,000 |
| BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | COM NEW | $136,234,886 | 17,878,594 |
| PARABILIS MEDICINES INC | PBLS | COM | $126,329,300 | 4,615,612 |
| RAPPORT THERAPEUTICS INC | RAPP | COM | $110,738,900 | 2,657,521 |
| ERASCA INC | ERAS | COM | $109,920,000 | 6,000,000 |
| EDGEWISE THERAPEUTICS INC | EWTX | COM | $101,981,300 | 2,510,000 |
| EYEPOINT INC | EYPT | COM NEW | $100,100,000 | 7,000,000 |
| ALUMIS INC | ALMS | COM | $92,456,671 | 3,285,596 |
| ABIVAX SA | ABVX | SPONSORED ADS | $89,950,500 | 675,000 |
| DIANTHUS THERAPEUTICS INC | DNTH | COM | $73,110,000 | 750,000 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.